 | Up a level |
2021
Heist, R. S., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Tanriverdi, O., Robeva, A., Le Mouhaer, S., Carbini, M., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial. Ann. Oncol., 32. S. S986 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Souquet, P-J., Kim, S-W., Solomon, B., Vansteenkiste, J. F., Carbini, M., Jary, A., Glaser, S., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study. Ann. Oncol., 32. S. S1033 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Ventouras, L-A., Menu, P., Wojtowicz, A., Zou, M., Diallo, S., Agostinho, A. Chassot, Tiedt, R. and Mina, M. (2021). The landscape of MET alterations in European cancer patients. Ann. Oncol., 32. S. S400 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041